- Explains the effect of bone marrow derived cells on the development of resistance to clinically practiced therapies
- Provides information on the availability of alternate therapies for recurrent glioblastoma when standard practices have failed
- Discusses targeting tumor microenvironment using available FDA approved drugs as an alternative treatment strategy for glioblastoma
1. Current status of recurrent glioblastoma therapies 2. Imaging of glioblastoma recurrence 3. Overarching therapeutic challenges and arachidonic acid metabolism as a novel target in glioblastoma 4. The intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies 5. Targeting Glioma Stem Cell Metabolism to Enhance Therapy Responses and Minimize Resistance 6. TBA Pros and cos of immunotherapy 7. TBA Glioblastoma resistance and convection therapy 8. TBA Sensitization of resistant GBM to radiation
Ali Syed Arbab, MD PHD, is Leader of Tumor Angiogenesis Initiative and Director, Core Imaging Facilities for Small Animals, both at Augusta University. Dr. Arbab's laboratory is devoted to determining the mechanisms of therapy resistance by focusing on the involvement of bone marrow derived cells in modulating the tumor microenvironment and initiating tumor neovascularization in glioblastoma models. To understand the involvement of bone marrow cells in developing resistance to antiangiogenic therapies (AAT), his group has developed chimeric animal models where bone marrow of the recipient animal is replaced with GFP+ bone marrow. Dr. Arbab's group documented that tumor-recruited bone marrow cells are a predominantly heterogeneous myeloid cell population that can predict therapeutic response in cancer, and they are using several strategies to target bone marrow or tumor-promoting myeloid cells to potentiate the anti-tumor effect of FDA-approved drugs in preclinical models of glioblastoma.